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Ethics of non-therapeutic research on imminently
dying patients in the intensive care unit
Nicholas Murphy   ,1,2 Charles Weijer   ,1,2,3 Derek Debicki,4,5 Geoffrey Laforge,5,6
Loretta Norton,7 Teneille Gofton,4 Marat Slessarev1,5
ABSTRACT
Non-therapeutic research with imminently dying patients
in intensive care presents complex ethical issues. The
vulnerabilities of the imminently dying, together with
societal disquiet around death and dying, contribute to
an intuition that such research is beyond the legitimate
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to an ongoing study, we demonstrate how our question-
driven approach is well suited to guiding investigators
and research ethics committees.
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material is published online
only. To view, please visit the
journal online (http://d x.doi.
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Non-
therapeutic research with imminently dying
patients in the intensive care unit (ICU) presents
complex ethical issues. Systematic research of
this kind is hindered by several ethical challenges,
including difficulties obtaining consent for research
participation, the ICU as a research environment,
the potential for study interventions to interfere
with routine end-of-life care and the vulnerability
of imminently dying patients.1–4
In this article, we describe a systematic approach
to managing ethical issues in research with imminently dying research participants in the ICU. To
enable rapid translation to practice, we provide a
checklist of eight ethical questions that researchers
and research ethics committees must satisfactorily
answer prior to conducting any research with this

patient population. To illustrate the advantages
of this question-
driven approach, we apply it to
our Canadian research programme, Neurologic
Physiology after Removal of Therapy (NeuPaRT).
We demonstrate that, provided adequate protections are in place, research with imminently dying
research participants is ethically justifiable.

The NeuPaRT study

In controlled organ donation after circulatory
determination of death (cDCDD), patients with
poor prognosis undergo withdrawal of life-
sustaining measures (WLSM) and progress to circulatory arrest. Following initiation of WLSM and
continuing postmortem, organs suffer ischaemic
damage and may become unsuitable for transplantation; hence, surgical organ retrieval begins as soon
as possible following the donor’s death. To preclude
the possibility of cardiac autoresuscitation, death
is declared after a mandatory 5 min ‘hands-
off ’
period following circulatory arrest, after which
organ retrieval commences5 (figure 1).
Current cDCDD protocols assume permanent
loss of brain activity within the ‘hands-off ’ period.6
While this assumption is rooted in physiological
principles, lack of confirmatory data from patients
contributes to unease among a proportion of stakeholders.7 8 Concern stems from the remote possibility that some donors could retain residual brain
function during organ retrieval, exposing them
to harm and violating the dead donor rule—the
injunction that organ retrieval cannot be the cause
of donor death.9
By documenting when brain activity ceases relative to circulatory arrest after WLSM in the ICU,
NeuPaRT will provide data to inform the timing of
death determination in cDCDD (figure 2). Specifically, we use transcranial Doppler (TCD) to measure
cerebral blood flow velocity, 10-
20 international
system video electroencephalogram (v-
EEG) to
capture cerebral electrical activity, somatosensory evoked potentials (SSEPs) to measure cortical
activity, brainstem auditory evoked potentials
(BAEPs) to measure brainstem activity, and pre-
existing routine monitoring to record arterial pulse
pressure, cardiac electrical activity and oxygen saturation (online supplemental material). While these
interventions will provide valuable scientific information, their use in research with imminently dying
patients poses ethical challenges (table 1).

MATERIALS AND METHODS

Using existing ethical guidelines for research with
human participants, we describe a systematic
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Figure 1 The process of controlled organ donation after circulatory determination of death begins with a decision to
withdraw life-sustaining measures and ends with postmortem organ recovery.
framework for the ethical design and conduct of research involving
imminently dying patient participants in the ICU. To enable
rapid translation to practice, we frame the approach in the form
of eight ethical questions that researchers and research ethics
committees ought to answer prior to conducting any research
with imminently dying patients. The scope of this paper is
limited to ethical issues and does not include an analysis of legal
issues. Researchers should be aware of and follow legal requirements for surrogate decision-making and research.

Research with the dying patient

Most studies involving dying patients take place in the context
of palliative care, which encompasses patients who have weeks
or months left to live. Ethically conducted research in palliative care includes both therapeutic interventions which offer the
prospect of direct benefit, as well as non-therapeutic research
involving observation, interviews or other non-
therapeutic
interventions.10 11 Patients in palliative care can often give
informed consent and may also benefit directly from research
participation.12
Research on imminently dying patients—that is, those who
have hours or minutes left to live—differs in important respects
from research in palliative care. Researchers are typically unable
to obtain first-person consent, nor are patients likely to benefit
from participation. While studies involving imminently dying
patients are not unknown,13 research intruding into the dying
process presents challenges unfamiliar to most researchers.
Together, these features distinguish research with the imminently dying from other areas of inquiry.
Patients who are imminently dying are vulnerable because
they are at an identifiably increased risk of greater or additional
wrongs in research.14 Specifically, they are at risk of autonomy
wrongs, such as being treated as mere means to research ends.
They are liable to justice-
related wrongs through exploitation, or from institutional or professional gatekeeping unfairly
preventing research participation. Finally, they are prone to
welfare wrongs if the research impedes the provision of end-of-
life care.
Suggesting that the vulnerability of the imminently dying
precludes research participation is paternalistic and—as with

palliative patients—may itself represent an unjust exclusion
from research. Furthermore, excluding this population from
research would compromise future patients (and organ donors)
who stand to benefit from greater understanding of the dying
process. While the vulnerability of the imminently dying complicates the application of accepted ethical principles guiding the
design and conduct of research, there is no compelling reason
why they should be excluded from research provided adequate
protections are in place.
All research involving human participants is guided by the
ethical principles of justice, respect for persons and beneficence.15 16 These principles entail normative guidelines for the
protection of research participants (table 2).
Further to the usual protections afforded research participants, additional protections for incompetent patients in
research are required.15–17 These additional protections may
include:
► Answering the study question must require the inclusion of these vulnerable participants; that is, their inclusion in research must not be solely for administrative
convenience.15–17
► The risks of non-therapeutic study procedures must be no
more than ‘minimal risk’.16–18
► Prospective consent for research participation must be
obtained from an authorised surrogate decision maker
familiar with the patient’s prior expressed wishes (if any),
values and interests.15–17
Finally, recent scholarship in research ethics highlights the
need to ensure protections for ‘bystanders’, that is, people who
are not research participants but who are nonetheless impacted
by research.19
The above normative precepts suggest eight ethical questions
that must be addressed prior to conducting any non-therapeutic
research with the imminently dying (table 3). To inform investigators and research ethics committees considering research with
this population, we describe our answers to these questions in
the context of the NeuPaRT study.

Figure 2 Neurologic Physiology after Removal of Therapy involves 30 min of baseline recording prior to withdrawal of
life-sustaining measures and 30 min of recording following asystole. BAEP, brainstem auditory evoked potential; SSEP,
somatosensory evoked potential; TCD, transcranial Doppler; v-EEG, video electroencephalogram; WLSM, withdrawal of
life -sustaining measures.
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Table 1

Neurologic Physiology after Removal of Therapy: study details
Study detail

Background

In controlled organ donation after circulatory determination of death (cDCDD), permanent loss of brain activity is assumed (but not confirmed) to occur within
the hands-off period following circulatory arrest, after which organ retrieval surgery commences. Lack of confirmatory human data to support this assumption
contributes to anxiety around cDCDD protocol.

Aim

Provide data to inform the timing of death determination in cDCDD by documenting the temporal relationship between the cessation of neurological and
circulatory activities after WLSM in the ICU.

Study population

Adult patients undergoing planned WLSM in participating ICUs with the expectation that death will ensue within 24 hours. This population is representative of
the relevant cDCDD donor population.

Design

Prospective observational multicentre pilot feasibility study carried out over 3 years at five academic centres in Canada. n=80.

Data collection instruments Routine clinical monitors: arterial pulse pressure, cardiac electrical activity and oxygen saturation using standard clinical monitors. Non-therapeutic monitors:
cortical electrical activity using v-EEG; cerebral blood flow using TCD; brainstem function using BAEPs; cortical function using SSEPs. Two of four non-therapeutic
procedures on any given patient.
Data collection process

Recording spanning 30 min prior to WLSM and up to 30 min following circulatory arrest.

Data analysis

Using synchronised waveform data from each patient, we will establish the time of cessation of brain activity relative to circulatory arrest.

Outcome measures

Time of cessation of brain activity measured using non-therapeutic monitors, time of circulatory arrest.

BAEP, brainstem auditory evoked potential; ICU, intensive care unit; SSEP, somatosensory evoked potential; TCD, transcranial Doppler; v-EEG, video electroencephalogram; WLSM, withdrawal of
life-s ustaining measures.

RESULTS AND DISCUSSION
Does the study hypothesis require the inclusion of imminently
dying patients?

Justice requires that the burdens and benefits of research participation are distributed equitably. Vulnerable participants should
not be included in research merely as a matter of convenience.
Hence, justifying the inclusion of vulnerable people demands a
compelling reason why a study question can only be answered
with their inclusion.
To inform the practice of cDCDD, NeuPaRT seeks data on
the temporal relationship between cessation of circulatory and
neurological activities during the dying process. This question
can only be addressed in a controlled ICU environment with
patients who are representative of the relevant donor population: imminently dying patients undergoing WLSM.

Are non-therapeutic risks and burdens minimised consistent
with sound scientific design?

The ethical principle of beneficence requires, inter alia, that
the risks and burdens from non-
therapeutic procedures are
minimised consistent with sound scientific design. To minimise intrusiveness while balancing the need to maximise the
contribution of each patient, any given NeuPaRT participant
undergoes no more than two of the four non-therapeutic study
procedures. Further, we make use of clinical monitoring already
in place where possible, thereby reducing research-related risks
and burdens on participants.20 Limiting the number of non-
therapeutic procedures that any one patient may undergo and,
where possible, using clinical monitoring already in place, minimises risks and burdens to participants while allowing sufficient
data to be collected to answer the study question.
Table 2

The set-
up of research equipment and any impact on the
medical care of the patient are important potential risks and
burdens that must be minimised consistent with sound scientific
design. Depending on researcher availability, site location and
data collection procedures, non-therapeutic equipment set-up
takes up to 1 hour. Contingent on the scheduled time of WLSM,
this sometimes calls for a delay before initiation of WLSM. It is
conceivable that delayed withdrawal could prolong suffering in
patients who retain any degree of consciousness. Furthermore, it
is crucial that the presence of researchers does not interfere with
routine care or otherwise disrupt interactions between patient,
family and significant others and staff.
To minimise risks to welfare and mitigate any changes to the
dying process for NeuPaRT participants, the standard of care
for patients undergoing WLSM is followed. Routine preparation
for withdrawal continues during equipment set-up, including
administration of analgesic and anxiolytic medications. There
are no restrictions on clinical staff activities. Researchers do not
participate in care and are not present in the room after study-
related equipment set-
up. The impact of study participation
on end-of-life care is comparable to other accepted procedures
undertaken for the benefit of others, such as preparation for
organ donation.

Are the risks of non-therapeutic procedures no more than
minimal risk?
Unlike study interventions that may directly benefit participants, procedures administered without therapeutic warrant
are subject to a threshold of permissible risk.20 Beneficence
requires that any non-
therapeutic risks faced by vulnerable
participants are minimal. In Canada, ‘minimal risk’ is defined

Principles of research ethics and entailed normative guidelines

Principle

Definition

Normative guidelines

Justice

The potential benefits, risks and
burdens of research participation
must be distributed equitably.

Fair procedures must be in place for the selection of research participants.
Vulnerable research participants are entitled to additional protections.

Respect for
persons

Candidates for research participation Informed, comprehending and free consent must be obtained from prospective research participants.
must be treated as autonomous
When prospective participant autonomy is diminished or lacking, informed consent must be obtained from an authorised surrogate
agents, and those with diminished
decision maker.
autonomy are entitled to protection.
Protect the confidentiality of private information.

Beneficence

Research participants must be
protected from harm and their
welfare must be promoted.

Therapeutic procedures must satisfy equipoise.
Any risks of non-therapeutic procedures must be minimised consistent with sound scientific design, and reasonable in relation to the
knowledge to be gained.
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Table 3

Ethical checklist for research with imminently dying patients in the intensive care unit

Ethical question

Considerations

1. Does the study hypothesis require
the inclusion of imminently dying
patients?

Could the research question be answered using another, less vulnerable population?

2. Are non-therapeutic risks and
burdens minimised consistent with
sound scientific design?

Are clinically indicated interventions made use of where feasible?

If the research question cannot be answered with another population, is the sample size sufficient to answer the research question?
Are vulnerable participants provided additional protections?
Is standard of care followed so far as is possible?
How will interference with routine care be mitigated?
Will non-therapeutic interventions be as unobtrusive as possible?
Are plans in place to deal with participant distress or anxiety?
Does the protocol account for risks associated with any delay to WLSM?

3. Are the risks of these procedures no What are the risks of non-therapeutic study procedures?
more than minimal risk?
Are these risks minimal?
Are adequate procedures in place for the protection and storage of data and biological samples?
4. Are these non-therapeutic risks
What is the expected social value of the study?
justified insofar as they are reasonable Do the risks of non-therapeutic procedures stand in reasonable in relation to the anticipated benefits of the study?
in relation to the anticipated benefits
of the study?
5. Will valid informed consent be
Are plans for surrogate informed consent consistent with local regulations?
obtained from an authorised surrogate How will the risk of therapeutic misconception be addressed?
decision maker?
Who will approach surrogates for consent?
Where and when will consent discussions take place?
How will researchers assess the fitness of surrogates to offer informed consent, and how will they ensure approaches for consent do not
cause further distress?
Is the consent document written in lay terms?
Will surrogates be given adequate time to ask questions and consider the patient’s study participation?
How will surrogates be assured that refusal will in no way impact patient care?
6. How will incidental findings be
handled?

Are there any foreseeable incidental findings which could indicate a change in the course of care?
Is a plan in place for dealing with incidental findings?
Will individual findings be shared with surrogates? Will summary findings?

7. What additional steps are in place to Have families and significant others of patients who have died in the ICU been involved in study design and development of consent
protect families and significant others materials?
of research participants?
How will families and significant others be prepared for the study process?
Are supports in place to help them cope during the process?
How will impacts on families and significant others be minimised consistent with sound study design?
Will opportunities for meaning-making for families and significant others be facilitated by research staff? How?
Will summary findings be shared with families and significant others of participants?
8. What additional steps are in place to Have clinical staff been informed of the study and have any concerns raised by them been addressed adequately?
protect clinical staff and researchers? Are researchers well trained and familiar with end-of-life situations? Are they familiar with the patient population?
Are they trained and experienced in approach for consent?
Do researchers have resources to support them during and after discussion with surrogates and families?
ICU, intensive care unit; WLSM, withdrawal of life-sustaining measures.

as the risks encountered in the daily lives of the study population.17 The definition of minimal risk varies among jurisdictions and researchers should consult local ethical requirements.
Ensuring non-therapeutic risks are minimal is an ethical imperative because competent patients can decide for themselves the
research-related risk they are willing to undertake, while incompetent patients cannot. Further, researchers must ensure there
are adequate procedures in place for the protection and storage
of data and biological samples.
Non-
therapeutic components of the NeuPaRT protocol
include the addition of neurological monitoring and, in a
subgroup of participants, auditory or electrical stimuli at intervals throughout the dying process. The study involves four
non-therapeutic procedures, of which no participant undergoes
more than two: continuous v-EEG, TCD, SSEPs and BAEPs. To
reduce interference, all neurological monitors are positioned out
of the way of family and staff and set to ‘comfort’ mode so that
4

sound and display are off. Where this is not possible (BAEPs and
SSEPs), monitors remain out of view of family (table 4).

Video electroencephalogram

Full-montage v-EEG enables determination of the time at which
cerebral electrical activity ceases. Commonly used with critically
ill patients in intensive care,21 continuous v-EEG involves a standardised placement of EEG electrodes using the 10-20 international system to allow for adequate coverage of the head.22
[i] V-
EEG is non-
invasive, passively measuring cortical brain
activity. While there are no risks associated with this procedure,
the video component may be perceived as intrusive.

i
While we use conventional placements of electrodes, we use fewer.
Normal EEG has electrodes 6 cm apart. We use 10 cm placings because
measuring between longer distances allows greater ability to see cerebral
activity. See Stecker et al.23
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Table 4

Monitors employed in Neurologic Physiology after Removal of Therapy
Haemodynamic monitors

Monitor

ECG

Arterial line

Neurological monitors
Oxygen saturation
monitor

v-EEG

TCD

SSEPs

BAEPs

Standard of care?

Yes

Yes

Yes

Sometimes

No

No

No

Purpose

Cardiac electrical
activity

Pulse pressure

Oxygen saturation

Cortical electrical
activity

Cerebral blood
flow

Cortical function

Brainstem function

Potentially
burdensome?

 No

Yes

No

No

No

Yes

Yes

BAEP, brainstem auditory evoked potential; SSEP, somatosensory evoked potential; TCD, transcranial Doppler; v-EEG, video electroencephalogram.

EEG’s video component is necessary because EEG is sensitive
to artefact. Interpretation of EEG signals requires video recordings to eliminate confounders, such as staff or family and significant others touching the patient or their bed (which they are free
to do). The sensitivity of dying process may provoke uneasiness
at the prospect of recording. Available recommendations24–26 on
the ethical use of videography in research were of limited use
in this case, where the purpose and scope of recording is highly
circumscribed.
To allay privacy concerns and limit intrusiveness, the EEG
camera captures only the patient’s bed. Sound is not recorded.
Recordings are deidentified and stored in a secure database. If
data contamination is suspected, only the relevant frames of
video are reviewed. Only two researchers (TG and DD) have
access to the recordings, which will be destroyed 15 years after
study completion as per local institutional requirements.

Transcranial Doppler

TCD is a non-invasive procedure which uses ultrasound probes
to measure blood flow velocity in intracranial vessels. Once
signals are identified by study personnel, two probes are affixed
over the temples using a head harness. TCD allows for determination of the time of cessation of cerebral blood flow relative to
circulatory arrest.
While there are no physical risks associated with this procedure, the addition of the head harness may be uncomfortable for
participants who retain a degree of consciousness. Although this
is unlikely in sedated patients, consistent with standard of care a
bedside nurse monitors the patient for discomfort and administers analgesics as needed.

BAEPs and SSEPs

BAEPs and SSEPs are used in our study to determine the cessation of brainstem and cortical function, respectively, and provide
data to interpret whether cerebral electrical activity measured via
v-EEG represents brain function as opposed to activity. BAEPs
use a series of clicks at a volume of 60 dB delivered through an
earpiece,27 and SSEPs use an electrical stimulus administered to
the median nerve in the wrist.28 While no participant undergoes
both SSEPs and BAEPs, each could cause discomfort in residually
aware participants.
Phenomenologically, conscious adults experience BAEPs at a
volume of 60 dB as similar to a conversation between two adults
sitting 1 m apart. SSEPs are like dull but persisting electrostatic
shocks and described as mildly uncomfortable. Twenty-
four
healthy volunteers studied locally rated the overall mean of pain
of SSEPs as 2.51/10 (SD=2.04), with 1=no pain, 5=moderate
pain, 10=severe pain (Loretta Norton, personal communication, 28 April 2022). We limit the obtrusiveness of stimuli by
presenting to only one ear or one wrist and follow the American
Clinical Neurophysiology Society guidelines.28
Murphy N, et al. J Med Ethics 2022;0:1–8. doi:10.1136/medethics-2021-107953

While v-EEG and TCD pose no risks to participants, BAEPs
and SSEPs arguably pose welfare risks in the form of discomfort or anxiety. Since participants in our study are sedated, this
is unlikely; however, the possibility cannot be eliminated. Were
evoked potentials to cause a patient distress (as indicated by the
patient’s behaviour, heart rate or blood pressure), we would
immediately discontinue the procedure.

Are these non-therapeutic risks justified insofar as they are
reasonable in relation to the anticipated benefits of the
study?

Beneficence demands that study risks are reasonable in relation
to anticipated benefits. While the impact of NeuPaRT participation on end-of-life care is minimised and the risks posed do not
obviously exceed the minimal risk threshold, still they must be
justified with respect to the social value of the study.
The NeuPaRT study addresses scientific questions central to
organ donation. By failing to confirm permanent loss of brain
activity, the current approach to cDCDD may fail to protect
donors from harm. Conversely, should cessation of brain activity
precede circulatory arrest, the current approach may deny
donors the opportunity to bequeath optimally viable organs.
The comprehensive data collection procedures we employ are
necessary to rigorously demonstrate the temporal relationship
between cessation of brain and circulatory activity in cDCDD
candidates. This may dispel lingering doubts about residual brain
function and the appropriate timing of death determination
in cDCDD. The benefits to be gained from our study—better
outcomes for organ recipients, potentially increased quality and
quantity of transplantable organs, protection of future donors—
are substantial. As the risks to participants are minimal and the
social value of the study is high, we conclude it has an acceptable
benefit-harm profile.

Will valid informed consent be obtained from an authorised
surrogate decision maker?

When the prospective research participant is incompetent,
respect for persons requires consent from an authorised surrogate decision maker familiar with the patient’s prior expressed
wishes, values and interests. Yet the ICU environment and the
difficult circumstances attending a patient’s illness or injury are
obstacles to informed consent.3 4 Potential impediments include
therapeutic misconception (attributing clinical intent to research
activities), undue influence on the part of treating physicians and
the degree to which surrogates can make informed decisions in
an unfamiliar environment while experiencing distress or confusion about complex health information.4 29–31
Clinical staff are valuable partners for deciding whether to
approach family and significant others about patient participation. Before approaching a surrogate decision maker, researchers
5
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confer with nursing staff and inquire as to whether they think it
appropriate. If nursing staff are uncertain, researchers discuss
the possibility with a social worker familiar with the family. To
avoid further distressing families, researchers defer to the judgement of staff.
Feelings of reciprocity towards clinical staff could contribute
to instances of invalid consent.3 Additionally, surrogates may
fear that refusal will negatively impact quality of patient care.30
For these reasons, approaches for consent are initiated by our
researchers, and only after a decision has been taken on WLSM
and (when applicable) organ donation. In the consent process,
surrogates are informed that refusal of study participation will
not impact patient care.
Because the addition of neurological monitoring alters the
appearance of the patient, transparency is important to ensure
the surrogate is informed. To allow surrogates to visualise what
participation entails, the study’s letter of information includes
pictures of research equipment, as well as an image of a person
with neuromonitoring on an ICU bed (see online supplemental
file 1).
Therapeutic misconception occurs when the person providing
informed consent attributes clinical intent to non-therapeutic
research interventions.32 Surrogates may not perceive a distinction between routine clinical care in the ICU and research procedures. Having a researcher who is not part of the clinical team
approach the family and significant others for consent combats
therapeutic misconception by highlighting the distinction
between routine care and research.
Some of the patients in the study go on to become organ
donors. In these cases, surrogates could conflate procedures
required for organ donation with research interventions. For this
reason, researchers allow the donation team to approach surrogates first. Additionally, the consent document makes clear both
that data collection will not interfere with donation protocol
and that withdrawal from the study in no way affects the prospects of donation.

How will incidental findings be handled?

An incidental finding is a discovery about a research participant
made during research that is outside the scope of the study, and
which could indicate a change in care.17 Any research in which
the discovery of incidental findings is foreseeable requires plans
be in place for their management.33 One worry raised by the
research ethics board at our site concerned those participants
proceeding to cDCDD: how would we manage the discovery
of neurological activity after the ‘hands-off ’ period following
circulatory arrest required before death determination?
For two reasons, this eventuality cannot arise in our study.
First, cDCDD follows a well-defined protocol with which our
study does not interfere. Second, to provide families and significant others with privacy, researchers do not observe neuromonitors in real time. All data analyses and interpretation take place
offline. Hence, no incidental findings will arise.

What additional steps are in place to protect families and
significant others of research participants?

NeuPaRT is a useful illustration of when the scope of research
ethics guidelines can fail to account for impacts on third parties.
Families and significant others of patients involved in our study
are research ‘bystanders’: non-participants who may be impacted
by research activities.19 Already at risk of psychological harm
from traumatic experience in the ICU,34 and sometimes in a state
of anticipatory grief,29 family members are themselves vulnerable. While not encompassed by research ethics guidelines, it
6

is imperative to minimise the impact of changes to end-of-life
processes which could adversely impact families.
In our study, participants’ families and significant others are
encouraged to remain at the bedside as the research is conducted.
There are no restrictions on their interactions with the patient
or staff. If required, families are supported through the most
appropriate means, including social services and spiritual care.
Studies on family experience in organ donation highlight how
delayed initiation of WLSM for the purposes of donor workup
can be distressing for families.35 36 The lesser delay sometimes
required for our study set-up could be experienced similarly.
To mitigate impact stemming from delay, families and significant others are informed of the time required for set-up during
the consent process. Following clinical determination of death,
monitoring continues for an additional 30 min with those participants not proceeding to organ donation. This duration was
acceptable to participants’ families in a similar study measuring
cardiac activity during the dying process.13
Because several study procedures alter the appearance of
participants, families and significant others may find the presence of additional monitors, probes and leads confronting. The
images of the study monitoring devices and their placement in
the study’s letter of information are thus integral to preparing
families. Survey and interview data2 37 and high consent rates
from a pilot study using neurological monitoring at end of life
(specifically, non-therapeutic EEG) suggest that families do not
find neuromonitoring overly invasive.38
Further, family members may perceive study involvement as
a benefit for the family. Families may derive meaning from the
loss of a loved one by helping to contribute to the production
of scientific knowledge.37 Families may find value in their role
in fulfilling the prior expressed wish of the patient to participate in research or, more generally, in enabling socially valuable research. To facilitate such meaning-making for families
and significant others, we communicate the social value of the
research, and we plan to provide families with summary research
findings after peer review and publication.
Finally, we believe that researchers should engage families and
significant others of patients who have died in the ICU in the
study design process and the preparation of consent materials.
The direct involvement of families in the research process will
help ensure that study procedures are conducted in a way that
families and significant others will find acceptable and that their
information needs are met.

What additional steps are in place to protect clinical staff and
researchers?

An often overlooked aspect of the conduct of research in the
ICU is the potential for a study to impact clinical staff and
researchers.39 This is a particularly relevant concern in our study,
where these stakeholders must navigate an emotionally fraught
environment.
ICU clinical staff have extensive experience with end-of-life
situations, and healthcare professionals are generally supportive
of observational research conducted at the end of life.10 39 Prior
to commencing enrolment, we offered a series of presentations
on the scope, aims, social value and procedures of the study. Staff
received handouts summarising key information, and after each
session we allowed time for questions and concerns. A similar
study involving imminently dying patients reported approval of
the research among staff.2
Researchers involved with studies on the imminently dying
could find the experience emotionally draining or otherwise burdensome insofar as they may feel they are inserting
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themselves into a sensitive and private moment.39 Additionally,
logistical challenges (eg, consent with larger families, broaching
a difficult topic) are demanding and may cause frustration or
unease.
Ensuring that researchers are adequately trained for research
in this setting is not only an issue of competency, it protects families and researchers from needless misunderstanding and conflict.
We ensure that our researchers are experienced in approaching
families and significant others for consent for research in the
ICU. They are familiar with both the patient population and
the testing techniques involved. Researchers use a consent script
that addresses the difficulties families and significant others
are facing. This resource is specific to our study and provides
researchers with aids for navigating an emotionally sensitive
environment.

CONCLUSION

While research with imminently dying patients in intensive care
poses ethical challenges, the NeuPaRT experience demonstrates
that such research can be conducted ethically. Our systematic
checklist of eight ethical questions to answer before conducting
non-therapeutic research with the imminently dying will guide
researchers and research ethics committees considering similar
research.
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